| scholarly article | Q13442814 |
| P2093 | author name string | Maurizio Salvadori | |
| Elisabetta Bertoni | |||
| P2860 | cites work | Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial | Q83059944 |
| Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys | Q83387311 | ||
| Novel strategies in immunosuppression: issues in perspective | Q83632643 | ||
| Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study | Q84028906 | ||
| Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy | Q84066133 | ||
| A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) | Q84102539 | ||
| Immunosuppression: does one regimen fit all? | Q84143487 | ||
| Using donor-specific antibodies to monitor the need for immunosuppression | Q84149083 | ||
| Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? | Q84589004 | ||
| De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure | Q84752864 | ||
| Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy | Q84870337 | ||
| Chronic renal failure after transplantation of a nonrenal organ | Q28204928 | ||
| Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure | Q33339056 | ||
| Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination | Q33345776 | ||
| Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study | Q33521348 | ||
| Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study | Q33522450 | ||
| Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. | Q34290459 | ||
| Alemtuzumab induction in renal transplantation | Q34660489 | ||
| Calcineurin inhibitor nephrotoxicity | Q34945314 | ||
| Immunosuppression minimization: current and future trends in transplant immunosuppression | Q35159346 | ||
| Strategies for minimizing immunosuppression in kidney transplantation | Q35990853 | ||
| Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials | Q36155850 | ||
| A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression | Q36447586 | ||
| Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence | Q36653136 | ||
| Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients | Q36677625 | ||
| Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics | Q37209745 | ||
| Can immune monitoring help to minimize immunosuppression in kidney transplantation? | Q37258707 | ||
| Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. | Q37421212 | ||
| Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases | Q37653018 | ||
| The (re)emergence of B cells in organ transplantation | Q37770912 | ||
| Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation | Q37858189 | ||
| Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation | Q37939057 | ||
| The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 | ||
| Are calcineurin inhibitors-free regimens ready for prime time? | Q38012603 | ||
| Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 | ||
| Cyclosporin and renal graft histology | Q39558964 | ||
| Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial | Q42171624 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. | Q42598004 | ||
| Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial | Q42612762 | ||
| Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. | Q42620122 | ||
| Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial | Q42621907 | ||
| Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. | Q42636572 | ||
| Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness | Q42649016 | ||
| Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation | Q42795564 | ||
| Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. | Q43067943 | ||
| Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids | Q43102233 | ||
| Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. | Q43178465 | ||
| Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial | Q43236444 | ||
| Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. | Q43239536 | ||
| Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients | Q43297611 | ||
| Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution | Q43620732 | ||
| Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation | Q43633987 | ||
| A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. | Q43680980 | ||
| Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation | Q43703063 | ||
| Chronic calcineurin inhibitor nephrotoxicity-lest we forget | Q43759235 | ||
| Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen | Q43862998 | ||
| Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study | Q43964548 | ||
| Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation | Q43984395 | ||
| A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). | Q44247085 | ||
| Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. | Q44260926 | ||
| Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant | Q44495681 | ||
| Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years | Q44524563 | ||
| Side effects and toxicity of immunosuppressive agents | Q44667042 | ||
| The natural history of chronic allograft nephropathy | Q44688416 | ||
| Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy | Q44800871 | ||
| De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. | Q45100299 | ||
| Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study | Q45153736 | ||
| Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study | Q45281312 | ||
| Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | Q45948071 | ||
| Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. | Q46007205 | ||
| Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial | Q46155747 | ||
| The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients | Q46233987 | ||
| A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up | Q46486529 | ||
| Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study | Q46510645 | ||
| Costimulation blockade with belatacept in renal transplantation | Q46569880 | ||
| Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus | Q46572818 | ||
| Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus | Q46645995 | ||
| Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation | Q46740554 | ||
| Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients | Q46763752 | ||
| Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial | Q46825301 | ||
| Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function | Q46825310 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus | Q46936585 | ||
| Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression | Q46983305 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. | Q50765005 | ||
| Predicting kidney graft failure by HLA antibodies: a prospective trial. | Q51038562 | ||
| Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. | Q52888129 | ||
| Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. | Q52889823 | ||
| A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. | Q54286979 | ||
| Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. | Q54505605 | ||
| Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. | Q54530926 | ||
| Can the nephron be spared? | Q54599994 | ||
| Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? | Q54661902 | ||
| Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids | Q56908156 | ||
| Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation | Q61945820 | ||
| Kidney Transplantation With Sirolimus and Mycophenolate Mofetil???Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs | Q61946028 | ||
| Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases | Q68129476 | ||
| Cyclosporine-associated chronic nephropathy | Q70376376 | ||
| Elective cyclosporine withdrawal after renal transplantation. A meta-analysis | Q70525158 | ||
| Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study | Q79576315 | ||
| Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency | Q79613466 | ||
| Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? | Q80369913 | ||
| Evolution and pathophysiology of renal-transplant glomerulosclerosis | Q80465077 | ||
| Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology | Q80783273 | ||
| Predicting subsequent decline in kidney allograft function from early surveillance biopsies | Q81214502 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 7-25 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | World journal of transplantation | Q27725045 |
| P1476 | title | Is it time to give up with calcineurin inhibitors in kidney transplantation? | |
| P478 | volume | 3 |
| Q39419895 | ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys |
| Q90465784 | Adverse Events and Discontinuation Rates Associated with Sirolimus Treatment in Adult Renal Transplant Patients in Latin America vs Non-Latin American Countries |
| Q38453650 | Avoiding immunological rejection in regenerative medicine. |
| Q38230449 | Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies |
| Q53702610 | Calcineurin inhibitors and nephrotoxicity in children. |
| Q30279164 | Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells |
| Q93074116 | Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results |
| Q41352306 | Effect of CD40 silenced dendritic cells by RNA interference on mice skin allograft rejection |
| Q38214871 | Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes |
| Q90599620 | High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression |
| Q26751433 | Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation |
| Q41313340 | Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes |
| Q36087779 | Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015? |
| Q43158054 | Moving Beyond Minimization Trials in Kidney Transplantation |
| Q40479200 | Surveillance Registry of Sirolimus Use in Recipients of Kidney Allografts From Expanded Criteria Donors. |
| Q33617408 | Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant |
| Q38237365 | Through a glass darkly: seeking clarity in preventing late kidney transplant failure |
| Q34761349 | What's new in clinical solid organ transplantation by 2013. |
Search more.